FP
AGIO icon

Flagship Pioneering’s Agios Pharmaceuticals AGIO Stock Holding History

Flagship Pioneering’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-965,369
Closed -$56.4M – 5
2017
Q1 		$56.4M Hold
965,369
– – 14.98% 4
2016
Q4 		$40.3M Hold
965,369
– – 13.11% 4
2016
Q3 		$51M Buy
+965,369
New +$42M 13.93% 3

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering's AGIO Position: Q2 2017 in Review

Flagship Pioneering sold out of Agios Pharmaceuticals (AGIO) in Q2 2017, closing a stake of 965,369 shares — an estimated $56.4M sold.

Flagship Pioneering first reported a position in AGIO in Q3 2016 and held it in 3 quarters. The position peaked at $56.4M in Q1 2017. 167 funds tracked by Wall St. Rank hold AGIO as of Q2 2017.

  • Flagship Pioneering reported no remaining Agios Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Flagship Pioneering sold 965,369 Agios Pharmaceuticals shares in Q2 2017, an estimated $56.4M.
  • Flagship Pioneering first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Flagship Pioneering's Agios Pharmaceuticals position peaked at $56.4M in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2017.

Based on Flagship Pioneering's 13F filing for Q2 2017, filed 2 Aug 2017.